Chi­nese deal­mak­ing: SARI nabs Italy’s NMS Group for $362M; In­ovio re­tools deal with Apol­lo­Bio

Two bio­phar­ma deals in­volv­ing Chi­nese com­pa­nies were an­nounced dur­ing the hol­i­days, mark­ing the be­gin­ning of what we ex­pect will be a boom­ing year for deal­mak­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.